216867-46-8

Basic information

• Product Name: 2-PYRIDIN-4-YL-THIAZOLE-5-CARBOXYLIC ACID
• Synonyms: 2-PYRIDIN-4-YL-THIAZOLE-5-CARBOXYLIC ACID;2-(4-Pyridyl)thiazole-5-carboxylic acid
• CAS NO: 216867-46-8
• Molecular Formula: C9H6N2O2S
• Molecular Weight: 206.22114
• Mol File: 216867-46-8.mol

Chemical Properties

• Boiling Point: 469.3±51.0 °C(Predicted)
• Appearance: /
• Density: 1.440±0.06 g/cm3(Predicted)
• PKA: 2.19±0.10(Predicted)
• CAS DataBase Reference: 2-PYRIDIN-4-YL-THIAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PYRIDIN-4-YL-THIAZOLE-5-CARBOXYLIC ACID(216867-46-8)
• EPA Substance Registry System: 2-PYRIDIN-4-YL-THIAZOLE-5-CARBOXYLIC ACID(216867-46-8)

Safety Data

• Hazardous Substances Data: 216867-46-8(Hazardous Substances Data)

Upstream product

• 216867-40-2 ethyl 2-(pyridin-4-yl)thiazole-5-carboxylate 
• 15854-87-2 4-iodopyridine 
• 41731-83-3 ethyl 2-bromo-1,3-thiazole-5-carboxylate 
• 1692-15-5 4-pyridylboronic acid 

Relevant articles and documents

CHEMICAL COMPOUNDS

A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.